Darolutamide cuts metastasis risk by 58% in high-risk prostate cancer
Darolutamide, the androgen receptor inhibitor developed jointly by Orion Pharma and Bayer, has demonstrated a statistically significant reduction in metastasis or death when added to standard-of-care androgen deprivation therapy (ADT) and radiation in prostate cancer patients at high risk of recurrence. Interim Phase 3 data presented at the ESMO Congress 2026 in a Presidential Symposium showed a hazard ratio of 0.42 (95% CI: 0.27–0.66; p=0.0001), corresponding to a 58% reduction in the risk of the combined primary endpoint of metastasis-free survival based on conventional imaging.
At a median follow-up of 3.8 years, the four-year metastasis-free survival rate was 95% in the darolutamide arm versus 88% in patients receiving placebo alongside ADT and radiotherapy. Secondary endpoints moved in the same direction: PSA progression-free survival improved by 53% (HR 0.47; 95% CI: 0.33–0.67), with four-year rates of 91% versus 83% for placebo. Prostate cancer-specific survival and overall survival hazard ratios were directionally favourable but not yet mature, with follow-up continuing.
Trial design and safety
The DASL-HiCaP study (NCT04136353) is an investigator-initiated, placebo-controlled Phase 3 trial run by the University of Sydney and the ANZUP Clinical Trials Group. It enrolled 1,106 participants across Australia, New Zealand, Canada, the United States, Ireland and the United Kingdom, randomised 1:1 to darolutamide 600 mg twice daily or placebo for 96 weeks alongside an LHRH analogue and locoregional radiotherapy. The protocol pre-specified an interim analysis after 87 metastasis-free survival events, meaning the current readout reflects a relatively early look.
The safety profile was broadly consistent with darolutamide's established tolerability. Grade 3 or above adverse events occurred in 43% of the darolutamide group versus 36% with placebo. Rates of fatigue, hypertension, fractures and cardiac events were similar between arms, which is relevant given that cardiac tolerability has been a differentiating point for darolutamide relative to some other androgen receptor inhibitors in earlier trials.
Market context and regulatory path
DASL-HiCaP is the fourth Phase 3 trial for darolutamide and its first in early-stage prostate cancer, extending the drug's evidence base beyond the metastatic hormone-sensitive (mHSPC) and non-metastatic castration-resistant (nmCRPC) settings in which it is already approved across more than 85 markets. Regulatory submissions for the high-risk recurrence setting have not yet been announced, and the companies are likely to await longer-term overall survival data before filing; the interim analysis was triggered by event count rather than time.
The prostate cancer market is highly competitive. Enzalutamide and apalutamide have established positions across similar patient populations, and the field is watching PSMA-targeted therapies with interest. Darolutamide's structural differentiation has historically centred on its low blood-brain barrier penetration and limited drug-drug interaction profile, characteristics that may matter more in an earlier-line, fitter population. A separate ongoing Phase 3 study, ARASTEP, is evaluating darolutamide in hormone-sensitive prostate cancer patients with biochemical recurrence and positive PSMA PET imaging, which could further widen the addressable population if successful. With around 1.5 million new diagnoses globally each year and projections pointing to 2.9 million by 2040, the commercial prize for any therapy demonstrating durable benefit earlier in the disease course is substantial.